Decreased biochemical progression in patients with castration-resistant prostate cancer using a novel mefenamic acid anti-inflammatory therapy: A randomized controlled trial

Prostate cancer (PCa) is the second most common non-dermatological cancer in men and is a growing public health problem. Castration-resistant disease (CRD) is the most advanced stage of the disease and is difficult to control. Patients with CRD may no longer accept conventional therapies as they are...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncol Lett
Autors principals: Guzman-Esquivel, José, Mendoza-Hernandez, Martha A., Tiburcio-Jimenez, Daniel, Avila-Zamora, Oscar N., Delgado-Enciso, Josuel, De-Leon-Zaragoza, Luis, Casarez-Price, Juan C., Rodriguez-Sanchez, Iram P., Martinez-Fierro, Margarita L., Meza-Robles, Carmen, Barocio-Acosta, Alejandro, Baltazar-Rodriguez, Luz M., Zaizar-Fregoso, Sergio A., Plata-Florenzano, Jorge E., Delgado-Enciso, Iván
Format: Artigo
Idioma:Inglês
Publicat: D.A. Spandidos 2020
Matèries:
Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7204620/
https://ncbi.nlm.nih.gov/pubmed/32391109
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/ol.2020.11509
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars